The Latest

  • A Bristol Myers Squibb employee works in one of the company's labs.
    Image attribution tooltip
    Permission granted by Bristol Myers Squibb
    Image attribution tooltip
    Q&A // Brain drug revival

    In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

    Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

  • Multi-racial group of scientists are researching and teamworking in a laboratory.
    Image attribution tooltip
    recep-bg via Getty Images
    Image attribution tooltip
    Sponsored by Pearson

    Measuring what matters: New priorities in COA selection

    Detecting meaningful change in rare disease trials requires more than statistics—it demands the right COA. Discover why sensitivity matters and how AI is transforming trial outcomes.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Should it successfully price, Parabilis would be the fifth biotech this year to go public after raising at least $700 million in private funding, a reflection of the more mature startups now pursuing IPOs.

    Updated May 22, 2026
  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly’s triple-acting obesity drug hits goal in Phase 3 trial

    Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.

  • Brain pipette
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Parkinson’s drug from Biogen, Denali comes up short

    High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.

    Updated May 22, 2026
  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    RA Capital banks $75M for a biotech SPAC

    Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers deepens AI investment with Anthropic deal

    The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.

  • Mathai Mammen, CEO, Parabilis Medicines
    Image attribution tooltip
    Permission granted by Parabilis
    Image attribution tooltip
    IPO window

    After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets

    Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.

  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin notches win in study that could expand use of top-selling medicine

    The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.

  • A person points to a CT scan of the lungs using a pen.
    Image attribution tooltip
    Vadym Plysiuk via Getty Images
    Image attribution tooltip
    Startup launches

    Oorja, run by Acceleron veterans, launches to make new fibrosis drugs

    The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly snaps up Engage to advance non-viral genetic medicines

    The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

    Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

  • People seen walking down Wall Street.
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    A migraine drugmaker heads to the public markets through reverse merger

    Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Two biotechs — radiopharmaceuticals specialist Full-Life Technologies and immune drugmaker Accro Bioscience — raised $160 million combined in a pair of equity financings announced Monday.

    Updated May 19, 2026
  • An illustration of Red and white blood cells inside a vein or artery.
    Image attribution tooltip
    SpiffyJ via Getty Images
    Image attribution tooltip

    Relay drug shows early promise against rare blood vessel diseases

    While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.

  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    Regeneron immunotherapy combo comes up short in melanoma trial

    A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    FDA approves AstraZeneca’s new kind of hypertension drug

    Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug

    The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin drug acquired in buyout misses goal in rare disease study

    Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects. 

  • Endometrial cancer cells in the uterus or cervix womb neck - closeup view 3d illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Merck ADC, licensed from China, hits mark in first big global trial

    The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.

  • An image of sodium ion channels
    Image attribution tooltip
    Permission granted by Stephanie Shiers, The University of Texas at Dallas
    Image attribution tooltip
    Deep Dive // Pain drugs

    A year after Vertex’s big launch, pain drug research faces a pivotal moment

    Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

  • India flag building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    India’s pharma industry is going global. But can it catch up to China?

    A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA hold puts Aardvark Prader-Willi drug in limbo

    The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

    Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.

  • Orange packages of mifepristone tablets rest against each other on a table.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Trump administration

    Supreme Court preserves access to abortion pill by mail

    The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by mail without requiring in-person visits.

  • An illustration of necrotic muscle fiber in Duchenne muscular dystrophy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

    Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”